We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Centers for Medicare & Medicaid Services should be more transparent about its plans for the Sept. 30 first release of Physician Payment Sunshine Act data, device and biotech groups say. Read More
Multiple device units manufactured for a single patient usually won’t need to be tallied separately under the FDA’s five-unit limit on custom devices, a new final guidance clarifies.
Read More
Whistleblowers who alleged CDRH read their personal emails cannot proceed with litigation at this time, according to a judge who said plaintiffs must first exhaust all administrative remedies to their claims. Read More
Manufacturers implementing unique device identification may choose a barcode for their Automatic Identification Data Capture technology, or they can use “any other technology that serves the same objectives,” new FDA guidance clarifies. Read More
Devicemakers are urging the Therapeutic Goods Administration to amend its low-value turnover exemption scheme for entries in the Australian Register of Therapeutic Goods to allow more small businesses to take advantage of it. Read More
Makers of low and moderate risk devices can now use the U.S. Food and Drug Administration’s de novo pathway to gain approval without first filing for 510(k) clearance — a route the agency hopes devicemakers will take. Read More
The Brazilian government is proposing major reforms to its public-private Product Development Partnership program, doubling the allowable length of PDP agreements from five to 10 years and establishing a committee to approve the projects. Read More
Devicemakers could see their wait time to begin clinical trials cut by more than a third under a proposed regulation calling for protocols to be reviewed in their entirety, rather than in stages, as is the current practice. Read More
Sponsors of Class II and Class III medical devices in China may bypass the need for clinical trials if they can show that the product is equivalent to a product listed in the country, new guidance says. Read More
European trade groups and industry experts were cautiously optimistic regarding news that medtech oversight will move from the health directorate to industry, with some saying it will boost innovation and access to new therapies and others worried it could derail progress on regulatory reforms in the EU. Read More